{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-024172","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.752774+00:00","generated_at":"2026-05-17T13:17:54.306649+00:00","sec_items":["1.01","3.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"bioAffinity closes $1.45M capital raise and reclassifies warrants adding $2.8M to equity","bullets":["Private placement of 990 Series B Preferred shares convertible into ~4.3M common at $0.23/sh and warrants for ~6.7M shares at $0.352/sh, gross proceeds ~$1.2M.","Warrant inducement: existing warrants exercised at reduced $0.23/sh for $253K cash; new warrants for 1.43M shares at $0.352/sh pending stockholder approval.","Warrant amendment reclassifies May 2025 warrants from liability to equity, increasing stockholders' equity by ~$2.8M.","Anti-dilution adjustment on May 2025 warrants reduces exercise price to $0.23/sh and increases shares issuable by ~8M.","Authorized common shares increased from 100M to 350M."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-024172","json":"https://secwatch.observer/filing/0001641172-25-024172.json","markdown":"https://secwatch.observer/filing/0001641172-25-024172.md","text":"https://secwatch.observer/filing/0001641172-25-024172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000164117225024172/0001641172-25-024172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000164117225024172/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:17:54.306649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e8bfe0eb4440dd69ae672cf83d43503b761bb5f9","claim":"bioAffinity Technologies, Inc.: Increased authorized shares of Common Stock from 100,000,000 to 350,000,000 and designated Series B Convertible Preferred Stock (effective 2025-08-13).","evidence_excerpt":"On August 13, 2025, the Company filed a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate of Amendment”) to increase the number of authorized shares of the Company’s Common Stock from 100,000,000 to 350,000,000.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000164117225024172/0001641172-25-024172-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-08-13"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}